696,829 Shares in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Acquired by Armistice Capital LLC

Armistice Capital LLC purchased a new stake in shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) in the second quarter, Holdings Channel.com reports. The fund purchased 696,829 shares of the company’s stock, valued at approximately $3,373,000. Armistice Capital LLC owned 0.14% of NeuroBo Pharmaceuticals at the end of the most recent quarter.

Separately, Affinity Asset Advisors LLC bought a new stake in shares of NeuroBo Pharmaceuticals during the second quarter worth $432,000. Hedge funds and other institutional investors own 1.37% of the company’s stock.

NeuroBo Pharmaceuticals Stock Performance

Shares of NASDAQ:NRBO opened at $3.29 on Friday. The business has a fifty day moving average of $3.74 and a 200-day moving average of $3.97. NeuroBo Pharmaceuticals, Inc. has a twelve month low of $2.90 and a twelve month high of $6.75.

NeuroBo Pharmaceuticals (NASDAQ:NRBO) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.38) by ($0.47). As a group, research analysts forecast that NeuroBo Pharmaceuticals, Inc. will post -4.39 earnings per share for the current year.

NeuroBo Pharmaceuticals Profile

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.